Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ-mediated Immunotherapy

ABSTRACT: We have employed a single cell sequencing approach using 10x Genomics scRNAseq to study the anti-tumoral effects of NanoCa. Our results have shown that NanoCa activates the innate immune response by inducing IFNβ, to investigate which types of cells are involved in the anti-tumor effect, CT26 tumor and Tumor-draining lymph nodes were isolated and analyzed using scRNA-seq.

ORGANISM(S): Mus musculus

PROVIDER: GSE299449 | GEO | 2026/06/09

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ-mediated Immunotherapy [BMDC]

Project description:We have employed RNA sequencing (RNA-seq) to investigate the effects of NanoCa on the activated innate immune response. Our results indicate that NanoCa activates the innate immune response by inducing interferon beta (IFNβ). To examine the transcriptional changes of its associated cytokines, dendritic cells derived from bone marrow were isolated and analyzed using RNA-seq.

2026-06-11 | GSE299525 | GEO

Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ-mediated Immunotherapy

Project description:Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ-mediated Immunotherapy

| PRJNA1274461 | ENA

Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ-mediated Immunotherapy [BMDC]

Project description:Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ-mediated Immunotherapy [BMDC]

| PRJNA1274904 | ENA

Effects of the treatment with IFNβ and GM-CSF-secreting CT2A cells to wildtype CT2A tumor microenvironment post resection

Project description:To elucidate the underlying immune responses elicited by IFNβ and GM-CSF-secreting CT2A cells to brain tumor microenvironment post resection compared to placebo group and non-IFNβ and GM-CSF-secreting CT2A cell group

2022-11-09 | GSE217253 | GEO

EBV latent nuclear antigen EBNA3A modulates IRF3-dependent IFNβ expression

Project description:Epstein-Barr virus (EBV) persistently infects over 90% of the human population and is the causative agent of infectious mononucleosis and human cancers. For the establishment of life-long infection, EBV tampers with the induction of type I interferon (IFN I)-dependent antiviral immunity in the host. How various EBV latency genes help orchestrate this crucial strategy is incompletely defined. Here, we reveal the mechanism by which the EBV nuclear antigen 3A (EBNA3A) inhibits IFNβ induction. Using proximity biotinylation we identify the histone acetyltransferase P300, a member of the IFNβ transcription complex, as a binding partner of EBNA3A. Follow-up experiments further demonstrate that EBNA3A also interacts with the activated IFN-inducing transcription factor IRF3 that collaborates with P300 in the nucleus and both events are mediated by the N-terminal domain of EBNA3A. Mechanistic studies reveal that EBNA3A reduces the binding of IRF3 to the IFNβ promotor, thereby hampering downstream IFN I signaling. These results reveal a novel mechanism by which viral immune evasion takes place.

2025-05-06 | PXD038572 | Pride

Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [low]

Project description:The current project is designed to evaluate the utility of proteomics in identifying pharmacodynamic (PD) biomarkers for biosimilarity assessment. This is an extension of the data submitted in GSE207945 which profiled longitudinal plasma samples from healthy subjects treated with single therapeutic doses/high doses of IFNβ-1a (30 μg) or Pegylated IFNβ-1a (125 μg) or placebo, to identify candidate PD biomarkers for the two biologics (n=248 for IFNβ-1a and N=528 for pegIFNβ-1a). The current project is a continuation study profiling longitudinal plasma samples from healthy subjects treated with a low dose of IFNβ-1a (7.5 μg) and pegIFNβ-1a (31.25 μg). In the current study, we reproduced the previous PD biomarker candidate responses at an intermediate/lower dose IFNβ-1a (15 μg) and pegIFNβ-1a (62.5 μg), and further characterized their PD response using characteristics such as significant area under the effect curve, dose-response, temporal profile and return to baseline, variability and sensitivity of the biomarker with sensitive doses on the steep portion of the dose-response curve and mechanism of action using the three tested dose-groups (high, intermediate and low) in the study.

2026-06-23 | GSE300489 | GEO

Characterizing circulating pharmacodynamic biomarkers of IFNβ-1a biologics [inter]

Project description:The current project is designed to evaluate the utility of proteomics in identifying pharmacodynamic (PD) biomarkers for biosimilarity assessment. This is an extension of the data submitted in GSE207945 which profiled longitudinal plasma samples from healthy subjects treated with single therapeutic doses/high doses of IFNβ-1a (30 μg) or Pegylated IFNβ-1a (125 μg) or placebo, to identify candidate PD biomarkers for the two biologics (n=248 for IFNβ-1a and N=528 for pegIFNβ-1a). The current project is a continuation study profiling longitudinal plasma samples from healthy subjects treated with an intermediate/lower dose of IFNβ-1a (15 μg) and pegIFNβ-1a (62.5 μg). Here, we reproduced the previous PD biomarker candidate responses at a lower dose, and further characterized their PD response using characteristics such as significant area under the effect curve, dose-response, temporal profile and return to baseline, variability and sensitivity of the biomarker with sensitive doses on the steep portion of the dose-response curve and mechanism of action using all three tested dose groups (high, intermediate and low).

2026-06-23 | GSE300488 | GEO

IFNβ expression is restricted to a subpopulation of splenic pDCs exhibiting a specific immune modulatory transcriptome signature

Project description:Type I IFNs are critical in initiating protective antiviral immune responses and plasmacytoid DCs (pDCs) represent a major source of these cytokines. Here we show that only few pDCs are capable to produce IFNβ after virus infection or CpG stimulation. Utilizing IFNβ/YFP reporter mice, we identify these IFNβ-producing cells in the spleen as a CCR9+CD9- pDC subset exclusively localized within the T/B cell zones. IFNβ-producing pDCs exhibit a distinct transcriptome profile with higher expression of genes encoding cytokines and chemokines, facilitating T cell recruitment and activation. These distinctive characteristics of IFNβ-producing pDCs are independent of the type I IFN receptor mediated feedback loop. Furthermore, IFNβ-producing pDCs exhibit enhanced CCR7-dependent migratory properties in vitro and in a peritoneal inflammation model they effectively recruit T cells in vivo. We define “professional type I IFN-producing cells” as a distinct subset of pDCs specialized in coordinating cellular immune responses.

2015-05-27 | GSE68788 | GEO

CDK10 suppresses nucleic acid sensors-mediated antitumor immunity [RNA-Seq]

Project description:Cdk10 knockout significantly reduced CT26 tumor growth in immunocompetent BALB/c WT mice.To elucidate the molecular mechanisms by which Cdk10 suppresses anti-tumor immunity, we conducted transcriptomic analyses on WT and Cdk10 KO CT26 cells

2025-10-27 | GSE287054 | GEO

nCounter PanCancer mouse immune profiling in CT26-bearing mouse tumor treated with DSP-0509 combined with anti PD-1 antibody

Project description:Combinatio of DSP-0509, small molecule TLR7 agonist, with anti PD-1 antibody enhanced anti-tumor inflammatory tumor microenvironment in CT26 tumor.

2023-01-24 | GSE216890 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data